Clinical Trials Browser

Terminated × Rituximab × 90 days × Clear all

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone